Generation of Non-Toxic Mutants of Pathogenic Gram Negative Bacteria
- 詳細技術說明
- Technology SummaryResearchers at the University of Iowa have developed a potential vaccine with efficacy across various pathogenic gram negative bacteria. The vaccine is based upon a conserved portion of an LOS, known as conLOS, from Neisseria meningitidis. This element, GlcNAc-Hep2phosphoethanolamine-KDO2-LipidA, is common across a broad range of gram negative bacteria. Hence, the vaccine can elicit an immune response against bacteria such as: Neisseria meningitides, Neisseria gonorrhoeae, Haemophilus influenza, Chlamydia trachomatis, Pseudomonas aeruginosa, Bordetella pertussis, Vibrio cholera, among others. The endotoxin-based form of the vaccine can be used alone or in combination with a protein carrier (and other elements), and delivered as a vaccine. In an alternate vaccine format, the specific gram negative bacteria with a mutated htrB gene (which produces the mutant LOS) can be used as a live cell vaccine that is specific for each of the gram negative bacteria listed above. AdvantagesMultiple FormatsVaccine can take any of three formats: Live cells with attenuated htrB gene; Mutated endotoxin; Mutated endotoxin conjugated to a carrier proteinBroad Spectrum Gram Negative TargetVaccine takes advantage of an endotoxin or gene that is common across various gram negative bacteriaPotential for Use in CombinationVaccine preparation could be combined with others and used to increase the efficacy and/or coverage of desired bacterial targets
- *Abstract
-
Background Information
Gram-negativebacteria have an outer membrane comprised of proteins, lipoproteins,phospholipids and glycolipids. Theglycolipids are consisted primarily of endotoxin-lipopolysaccharides (LPS) orlipooligosaccharides (LOS), depending on the bacteria. LPS and LOS areconsidered as bacterial components which have potential vaccine applicationsbecause of the antigenic determinants in their structures. However, the chemical nature of LPS and LOSprevents the use of these molecules in vaccine formulations – activeimmunization with LPS or LOS is unacceptable due to the inherent toxicity ofthe lipid A portion. The negative healtheffects induced by lipid A of LPS or LOS include fever, leucopenia, abortion,and in larger doses, shock and death. Accordingly, there are no currently available vaccines which induceantibody responses to LPS or LOS.
Patent
Awarded | US 7,510,717 B2
- *Licensing
- Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546
- 國家/地區
- 美國
